RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity

Br J Pharmacol. 2001 Sep;134(2):386-92. doi: 10.1038/sj.bjp.0704255.

Abstract

1. The serotonin(2C) (5-HT(2C)) receptor couples to both phospholipase C (PLC)-inositol phosphate (IP) and phospholipase A(2) (PLA(2))-arachidonic acid (AA) signalling cascades. Agonists can differentially activate these effectors (i.e. agonist-directed trafficking of receptor stimulus) perhaps due to agonist-specific receptor conformations which differentially couple to/activate transducer molecules (e.g. G proteins). Since editing of RNA transcripts of the human 5-HT(2C) receptor leads to substitution of amino acids at positions 156, 158 and 160 of the putative second intracellular loop, a region important for G protein coupling, we examined the capacity of agonists to activate both the PLC-IP and PLA(2)-AA pathways in CHO cells stably expressing two major, fully RNA-edited isoforms (5-HT(2C-VSV), 5-HT(2C-VGV)) of the h5-HT(2C) receptor. 2. 5-HT increased AA release and IP accumulation in both 5-HT(2C-VSV) and 5-HT(2C-VGV) expressing cells. As expected, the potency of 5-HT for both RNA-edited isoforms for both responses was 10 fold lower relative to that of the non-edited receptor (5-HT(2C-INI)) when receptors were expressed at similar levels. 3. Consistent with our previous report, the efficacy order of two 5-HT receptor agonists (TFMPP and bufotenin) was reversed for AA release and IP accumulation at the non-edited receptor thus demonstrating agonist trafficking of receptor stimulus. However, with the RNA-edited receptor isoforms there was no difference in the relative efficacies of TFMPP or bufotenin for AA release and IP accumulation suggesting that the capacity for 5-HT(2C) agonists to traffic receptor stimulus is lost as a result of RNA editing. 4. These results suggest an important role for the second intracellular loop in transmitting agonist-specific information to signalling molecules.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amphetamines / pharmacology
  • Animals
  • Arachidonic Acid / metabolism
  • Binding, Competitive / drug effects
  • Bufotenin / pharmacology
  • CHO Cells
  • Cricetinae
  • Dose-Response Relationship, Drug
  • Ergolines / metabolism
  • Inositol Phosphates / metabolism
  • Lysergic Acid Diethylamide / pharmacology
  • Piperazines / pharmacology
  • Protein Isoforms / genetics
  • Protein Isoforms / metabolism
  • Quipazine / pharmacology
  • RNA Editing*
  • Radioligand Assay
  • Receptor, Serotonin, 5-HT2C
  • Receptors, Serotonin / genetics
  • Receptors, Serotonin / metabolism*
  • Serotonin / pharmacology
  • Serotonin Receptor Agonists / metabolism*
  • Serotonin Receptor Agonists / pharmacology
  • Tritium

Substances

  • Amphetamines
  • Ergolines
  • Inositol Phosphates
  • Piperazines
  • Protein Isoforms
  • Receptor, Serotonin, 5-HT2C
  • Receptors, Serotonin
  • Serotonin Receptor Agonists
  • Bufotenin
  • Tritium
  • 1-(3-trifluoromethylphenyl)piperazine
  • Arachidonic Acid
  • Serotonin
  • Quipazine
  • Lysergic Acid Diethylamide
  • 4-iodo-2,5-dimethoxyphenylisopropylamine
  • mesulergine